What Is DSIP? The Delta Sleep-Inducing Peptide, Explained
DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence.
Peptide Medicine
Peptide research explained: molecular biology, clinical studies, formulation differences, and the evidence behind medical claims.
2,305reviewed articles
257topic clusters
Sep 5, 2026latest review
Why does the exact molecule matter?
Insulin, GLP-1 medicines, and experimental tissue-signaling peptides have different structures, targets, and evidence. A finding about one does not establish the effect of another. Even products containing the same ingredient can differ in formulation and delivery.
What can a mechanism tell us?
A mechanism explains how a molecule interacts with a biological system. It can suggest what researchers should test. It cannot by itself establish a clinical benefit, an effective regimen, or whether benefits outweigh risks.
For example, a change in growth hormone or IGF-1 is a biological measurement. A claim about strength, recovery, or healthspan needs evidence measuring that outcome in the relevant population.
How do the research questions differ?
These guides cover different kinds of evidence. The study product, population, route, and endpoint determine what a finding can support.
- BPC-157 and thymosin-related peptides: animal injury models and the limitations of translating them into clinical recovery claims.
- CJC-1295 and ipamorelin: hormone signaling and the distinction between biomarker changes and patient outcomes.
- GHK-Cu: skin and laboratory research, with topical and injectable questions considered separately.
- Tesamorelin: Egrifta evidence in adults with HIV-associated lipodystrophy and the importance of exact formulation.
- Semax and Selank: neurological and anxiety research, study design, and replication.
How should safety findings be compared?
A safety finding belongs to a specified product, route, population, and follow-up period. A small study may identify common short-term reactions while leaving uncommon or delayed effects unresolved. A topical study cannot establish the safety of an injection.
Does an online listing establish availability?
No. A seller listing, a research label, a prescription, and FDA approval are different things. FDA applies product- and ingredient-specific requirements. A bulk-substance nomination or advisory recommendation is not a final authorization to offer a substance.
When is a cost comparison meaningful?
A treatment-cost comparison needs a defined product and an evidence-based regimen. A price per vial cannot establish clinical value when the claimed course, benefit, or product equivalence has not been validated.
Peptide guides by molecule
- KPVkpv peptide
- SS-31ss-31 peptide
- DSIPdsip peptide
- Oxytocin Nasal Sprayoxytocin nasal spray
- GHK-Cughk-cu
- PT-141pt-141
- NAD+nad+ injection
- Glutathioneglutathione injection
- Semaxsemax
- Selankselank
- AOD-9604aod-9604
- BPC-157bpc 157
- TB-500TB-500
- Sermorelinsermorelin
- Tesamorelintesamorelin
- MOTS-cmots-c peptide
- Epitalonepitalon
- Thymosin Alpha-1thymosin alpha 1
Frequently asked questions
Are all peptides medicines?
No. Peptides are a molecular category that includes naturally occurring signals, research compounds, cosmetic ingredients, and some approved medicines.
Does a human study establish a treatment?
It depends on what the study measured. Early pharmacology studies, uncontrolled reports, and randomized clinical trials answer different questions.
Are topical and injectable forms equivalent?
No. Changing the route changes exposure and requires separate evidence about the formulation and its effects.
Does an advisory recommendation change approval status?
An advisory recommendation is not product approval or a final rule. The applicable formal FDA record determines what changed.
Explore treatments available through HealthRX.com
Compare pricing, plan options and the online visit process.
High-intent clinical paths
What Is Selank? The Tuftsin-Based Anxiolytic Peptide
Selank is a synthetic heptapeptide derived from tuftsin, studied mainly in Russian labs for anxiety and cognition, with no FDA-approved use.
Editorial: KPV's Evidence Is Better Than Most Peptides', and Still Not Enough
KPV has more mechanistic and animal data than most research peptides, but human trials are absent and no FDA enforcement discretion covers compounding it as of Sept 2026.
Browse by clinical intent
Tissue and Injury Research
BPC-157 and thymosin-related research, injury models, and the gap between laboratory findings and clinical outcomes.
Growth Hormone Axis
CJC-1295, ipamorelin, sermorelin, and tesamorelin: hormone signaling, study populations, and product distinctions.
- CJC-1295 for Sarcopenia in Older Adults: A Clinical Protocol
- Peptide with TRT: What the Evidence Says About Combining Peptides and Testosterone
- CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output
- CJC-1295 Monitoring Schedule: Labs and Exams You Need
- CJC-1295 Pharmacogenomics: How Genetic Variability Affects Growth Hormone Response
Safety and Monitoring
Drug interactions, renal and hepatic considerations, pregnancy, adverse effects, and clinical guardrails.
- BPC-157 Complete Drug-Drug Interaction Profile
- TB-500 Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management
- TB-500 Renal Protection or Renal Risk: What the Evidence Actually Shows
- BPC-157 Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know
- TB-500 Safety Signals and FDA Actions: What Patients and Clinicians Need to Know
Peptide Medicine explorer
Showing 60 of 2,305 clinical reviews.
What Is DSIP? The Delta Sleep-Inducing Peptide, Explained
DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence.
What Is Selank? The Tuftsin-Based Anxiolytic Peptide
Selank is a synthetic heptapeptide derived from tuftsin, studied mainly in Russian labs for anxiety and cognition, with no FDA-approved use.
Editorial: KPV's Evidence Is Better Than Most Peptides', and Still Not Enough
KPV has more mechanistic and animal data than most research peptides, but human trials are absent and no FDA enforcement discretion covers compounding it as of Sept 2026.
KPV Nanoparticle Delivery: The Research That Changed Oral Peptides
Why hyaluronic-acid and nanoparticle KPV delivery matters for gut-targeted peptides, based on murine colitis studies, not human trials.
Stacking KPV with BPC-157: Rationale and Cautions
KPV plus BPC-157 is a compounding-community practice with no direct combination trials. Here's the mechanistic rationale and what remains unproven.
KPV vs BPC-157 for Gut Health: Different Tools, Different Jobs
KPV and BPC-157 both get used for gut inflammation, but their evidence and mechanisms differ. Here is how they compare and where each is unproven.
KPV vs TB-500: Comparing Two Post-Category-2 Peptides
KPV and TB-500 both lost FDA Category 2 nomination status and got favorable PCAC votes, but neither is FDA-approved or on the 503A list as of Sept 2026.
FDA Peptide Status Tracker: Category 2, PCAC Votes, and 503A (2026)
Live reference table tracking FDA regulatory status for 18 compounded peptides: Category 2 placements, withdrawals, PCAC votes, and 503A bulks list status.
BPC-157 Complete Drug-Drug Interaction Profile
What is actually known about BPC-157 drug interactions, including the absence of formal human interaction studies and the limits of animal evidence.
BPC-157 for Wound Healing: Off-Label Risks, Benefits, and What the Evidence Actually Shows
BPC-157 has no FDA-approved wound-healing use. This guide separates preclinical interest from the human evidence and explains when a wound needs clinical care.
TB-500 Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management
What to do after a suspected TB-500 dosing error, why no human toxic dose is established, and how product uncertainty changes emergency assessment.
TB-500 Renal Protection or Renal Risk: What the Evidence Actually Shows
What is known---and not known---about TB-500 (thymosin beta-4 fragment), kidney claims, and regulatory status.
BPC-157 vs GHK-Cu: Switching Between Them
A clinical comparison of BPC-157 pentadecapeptide and copper tripeptide GHK-Cu, including mechanisms, evidence, and practical guidance on switching between them.
CJC-1295 Manufacturer Copay Program: How to Lower Your Cost in 2026
There is no manufacturer copay card for CJC-1295. Check its FDA status, verify any pharmacy, compare written cash quotes, and confirm HSA or FSA rules before paying.
BPC-157 Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know
There is no validated BPC-157 dose for adolescents. Review the current FDA evidence, July 2026 compounding review, athlete rules, and safer next steps.
CJC-1295 for Sarcopenia in Older Adults: A Clinical Protocol
What human studies actually show about CJC-1295 for age-related muscle loss, how sarcopenia is diagnosed, and which exercise and nutrition treatments have clinical evidence.
Peptide with TRT: What the Evidence Says About Combining Peptides and Testosterone
A guide to the evidence and safety gaps for combining testosterone replacement therapy with CJC-1295, ipamorelin, BPC-157, TB-500, sermorelin, or bremelanotide.
TB-500 Safety Signals and FDA Actions: What Patients and Clinicians Need to Know
A source-verified review of TB-500 safety, FDA actions, human evidence, compounding status, product-quality risks, adverse-event reporting, and anti-doping rules.
Sermorelin Online: How to Get It, What It Costs, and Who It Actually Helps
A guide to getting sermorelin online, covering telehealth candidacy screening, compounded pricing, prescription requirements, and an honest look at the underlying trial evidence.
Egrifta (Tesamorelin) Online: Cost, Candidacy, and What the Evidence Shows
A guide to getting Egrifta (tesamorelin) online, including real pricing, telehealth steps, candidacy criteria, and trial data from Falutz et al. (NEJM 2007).
GHK-Cu Online: Cost, Candidacy, and How to Get It Through Telehealth
A guide to getting GHK-Cu online: what the peptide research actually shows, who qualifies, what it costs per month, and how the telehealth prescribing process works.
Epitalon Online: Cost, Prescription Requirements, and What the Research Actually Shows
A guide to getting Epitalon online: candidacy, typical cost, the telehealth prescription process, and an honest look at the evidence behind this investigational peptide.
MOTS-c Online: Cost, Candidacy, and How the Telehealth Process Works
A clear, evidence-graded guide to getting MOTS-c through telehealth: what the peptide is, what the 2015 Cell Metabolism study actually showed, realistic cost, and how a prescriber decides if it fits you.
TB-500 Patient Assistance for Low-Income: How to Reduce Your Out-of-Pocket Cost
TB-500 (thymosin beta-4 fragment) is not covered by insurance or traditional patient assistance programs. Learn realistic strategies to lower your cost for this compounded peptide.
Superpower Real Customer Outcomes: An Independent Review of Lab, GLP-1, and Peptide Services
Independent analysis of Superpower's subscription concierge model for lab testing, GLP-1 prescriptions, and peptide therapies. Real customer outcomes, pricing, clinical evidence, and how Superpower compares to alternatives.
CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output
A physician-level breakdown of how CJC-1295 (modified GRF 1-29) activates GHRH receptors, amplifies pulsatile GH release, and sustains IGF-1 elevation for up to 8 days through Drug Affinity Complex albumin binding.
CJC-1295 Monitoring Schedule: Labs and Exams You Need
A clinician-grade monitoring schedule for CJC-1295 (modified GRF 1-29), covering baseline labs, follow-up intervals, IGF-1 targets, safety markers, and when to adjust or discontinue therapy.
CJC-1295 Pharmacogenomics: How Genetic Variability Affects Growth Hormone Response
How pharmacogenomics and genetic variants in GHRHR, GH1, IGF1, and SOCS genes shape individual responses to CJC-1295 modified GRF. Evidence-based guide for clinicians and patients.
Copper Peptides Drug-Drug Interaction Table: A Prescriber and Pharmacist Reference
Complete drug-drug interaction (DDI) table for the copper peptides class, centered on GHK-Cu. Covers topical and systemic formulations, chelation conflicts, retinoid co-use, and monitoring guidance for polypharmacy patients.
Copper Peptides Monitoring Bundle: Lab Panels, Schedules, and Clinical Thresholds for GHK-Cu Prescribers
Evidence-based monitoring protocol for copper peptide (GHK-Cu) therapy covering baseline labs, ongoing surveillance intervals, serum copper and ceruloplasmin targets, hepatic panels, and discontinuation criteria for prescribing clinicians.
Healing Peptides (BPC-157 / TB-500) Adverse-Event Management Protocols
Evidence-based adverse-event management protocols for BPC-157 and TB-500 healing peptides, including grading scales, clinical decision points, dose modifications, and when to discontinue therapy.
Healing Peptides (BPC-157 / TB-500) Drug-Drug Interaction Table
Clinician-focused drug-drug interaction reference for BPC-157 and TB-500 healing peptides, covering known pharmacologic interactions, CYP considerations, and co-prescribing precautions.
Healing Peptides (BPC-157 / TB-500): Special-Populations Prescribing Summary
Evidence-based special-populations guide for BPC-157 and TB-500 (thymosin beta-4). Covers renal impairment, hepatic dysfunction, pediatrics, geriatrics, pregnancy, lactation, and immunocompromised patients at MD/PharmD level.
CJC-1295 vs MK-677 (Ibutamoren): Cost and Access Head-to-Head
A detailed cost and access comparison of CJC-1295 (modified GRF) and MK-677 (ibutamoren) for growth hormone optimization, including pricing, insurance coverage, compounding pharmacy availability, and clinical efficacy data.
CJC-1295 vs MK-677 (Ibutamoren): How to Switch Between Them Safely
Compare CJC-1295 (modified GRF 1-29) and MK-677 (ibutamoren) for growth hormone optimization. Learn switching protocols, clinical differences, and which peptide fits your goals.
Ipamorelin vs CJC-1295: Cost and Access Head-to-Head
Compare ipamorelin acetate and CJC-1295 (modified GRF 1-29) on price per vial, insurance barriers, pharmacy access, and clinical evidence for growth hormone release.
Sermorelin vs CJC-1295: How to Switch Between Them Safely
A clinical comparison of sermorelin acetate and CJC-1295 (modified GRF 1-29), including pharmacokinetics, efficacy data, and a step-by-step protocol for switching between these GHRH analogs.
Sermorelin vs Egrifta (Tesamorelin): Switching Between Them
A clinical comparison of sermorelin acetate and tesamorelin (Egrifta), including mechanisms, trial data, and practical guidance for switching between these GHRH analogs.
Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Switching Between Them
Clinical comparison of tesamorelin and ibutamoren (MK-677) for growth hormone optimization, including when and how to switch between these two peptides safely.
AOD-9604 vs MOTS-c: Switching Between These Peptides
A clinical comparison of AOD-9604 (HGH fragment 176-191) and MOTS-c mitochondrial peptide, including when and how to switch between them safely.
PT-141 (Bremelanotide) vs AOD-9604: Switching Between Them
Clinical comparison of PT-141 (bremelanotide) and AOD-9604 (HGH fragment 176-191), including mechanisms, indications, side effects, and how to switch safely between these specialty peptides.
Epitalon Cost vs. Alternatives: What You Actually Pay for Telomerase-Targeting Peptides
A clinical comparison of epitalon tetrapeptide pricing against TA-65, GHK-Cu, NAD+ precursors, and other longevity-class compounds, with mechanism breakdowns and evidence grading.
BPC-157 Safety in Black / African Ancestry Patients: What the Evidence Actually Shows
BPC-157 pentadecapeptide lacks ethnicity-stratified human trial data. This article covers pharmacogenomic factors, G6PD considerations, renal risk, and monitoring guidance for Black / African ancestry patients considering BPC-157.
BPC-157 in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations
Evidence review of BPC-157 pentadecapeptide efficacy in South Asian populations, covering pharmacogenomic variability, dosing considerations, and documented gaps in ethnicity-stratified clinical data.
BPC-157 Safety Profile Differences in South Asian Patients
Evidence-based review of BPC-157 pentadecapeptide safety considerations for South Asian individuals, including pharmacogenomic factors, cardiovascular risk at lower BMI thresholds, and dosing guidance.
CJC-1295 Black / African Ancestry Dose Adjustments
Evidence-based guide to CJC-1295 modified GRF dosing considerations for Black and African ancestry patients, including pharmacogenomic factors, GH axis variability, and clinical monitoring protocols.
CJC-1295 Safety Profile Differences in South Asian Patients
Evidence-based review of CJC-1295 (modified GRF 1-29) safety considerations for South Asian populations, including pharmacogenomic variation, cardiovascular risk at lower BMI thresholds, and clinical monitoring adjustments.
Ipamorelin Efficacy in Black and African Ancestry Patients: Documented Gaps and Pharmacogenomic Considerations
Evidence review of ipamorelin acetate efficacy differences in Black and African ancestry populations, covering pharmacogenomics, GH axis variability, GHSR polymorphisms, and race-stratified clinical data gaps.
Ipamorelin East Asian Dose Adjustments: Pharmacogenomics, Body Composition, and Clinical Guidance
Evidence-based guide to ipamorelin acetate dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, GH-axis variation, and practical dose-adjustment strategies.
Ipamorelin South Asian Dose Adjustments
Evidence-based guide to ipamorelin acetate dosing considerations for South Asian patients, covering pharmacogenomics, metabolic phenotype differences, body composition factors, and clinical monitoring protocols.
TB-500 South Asian Dose Adjustments: Pharmacogenomic and Clinical Considerations
Evidence-based guide to TB-500 (thymosin beta-4 active fragment) dosing considerations for South Asian patients, covering pharmacogenomics, body composition differences, and monitoring protocols.
TB-500 South Asian Documented Efficacy Gaps: Pharmacogenomics, Dosing, and What the Evidence Actually Shows
TB-500 (thymosin beta-4 active fragment) may behave differently in South Asian patients due to cardiovascular risk profiles, metabolic differences, and pharmacogenomic variation. Here is what the clinical and preclinical data reveal.
TB-500 in South Asian Patients: Safety Profile Differences and Pharmacogenomic Considerations
Evidence-based analysis of TB-500 (thymosin beta-4 active fragment) safety differences in South Asian populations, covering pharmacogenomics, cardiovascular risk modifiers, dosing considerations, and monitoring protocols.
Egrifta (Tesamorelin) South Asian Dose Adjustments
Evidence-based guide to tesamorelin dosing considerations for South Asian patients, including pharmacogenomic factors, metabolic risk differences, and clinical monitoring recommendations.
What Are Peptides? A Women's Health Guide
Peptides are short chains of amino acids that regulate hormones, metabolism, bone density, and more. This evidence-based guide explains how peptides work in women's health, which ones are FDA-approved, and what the research actually shows.
What Are Peptides? Types, Benefits, and Uses in Medicine
Peptide is a chemical description, not a safety rating. Compare approved peptide drugs, investigational molecules, compounded preparations, and research products by evidence and product status.
BPC-157 Effect on AST: What the Research Shows
Does BPC-157 raise or lower AST? We review the preclinical evidence on BPC-157 pentadecapeptide and aspartate aminotransferase, explain the proposed mechanism, and outline a practical monitoring schedule.
BPC-157 and Warfarin Interaction: Risks, Mechanisms, and Clinical Guidance
BPC-157 pentadecapeptide may alter warfarin's anticoagulant effect through angiogenic and nitric oxide pathways. Learn the risks, monitoring requirements, and what clinicians recommend before combining these two agents.
CJC-1295 and Warfarin Interaction: Risks, Monitoring, and Clinical Guidance
CJC-1295 (modified GRF 1-29) and warfarin have no direct published interaction data, but growth hormone axis stimulation can plausibly alter warfarin metabolism. What is known, what is mechanistically plausible, and what still needs verification.
Ipamorelin and Benzodiazepines Interaction: Safety, Risks, and Clinical Guidance
Can you take ipamorelin with benzodiazepines? Learn about the pharmacodynamic and pharmacokinetic considerations, CNS depression overlap, monitoring requirements, and dose-adjustment strategies.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.
